Notably, genetically reduced HbA1c via GIPR/GLP1R was associated with reduced T2D risk, with both loci demonstrating consistent, directionally aligned effects consistent with their intended therapeutic targeting of metabolic pathways (Table S12). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.